Abstract
Original language | English |
---|---|
Pages (from-to) | 285-292 |
Number of pages | 8 |
Journal | Mutagenesis |
Volume | 23 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2008 |
Fingerprint
Dive into the research topics of 'Radioprotective effect of sulfasalazine on mouse bone marrow chromosomes'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Radioprotective effect of sulfasalazine on mouse bone marrow chromosomes. / Mantena, S.K.; Unnikrishnan, M.K.; Uma Devi, P.
In: Mutagenesis, Vol. 23, No. 4, 2008, p. 285-292.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Radioprotective effect of sulfasalazine on mouse bone marrow chromosomes
AU - Mantena, S.K.
AU - Unnikrishnan, M.K.
AU - Uma Devi, P.
N1 - Cited By :4 Export Date: 10 November 2017 CODEN: MUTAE Correspondence Address: Unnikrishnan, M. K.; Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal 576 104, Karnataka, India; email: mkunnikrishnan@gmail.com Chemicals/CAS: salazosulfapyridine, 599-79-1; Radiation-Protective Agents; Sulfasalazine, 599-79-1 Manufacturers: Sigma, United States References: Monig, H., Messerschmidt, O., Streffer, C., Chemical radioprotection in mammals and in man (1990) Radiation Exposure and Occupational Risks, pp. 97-143. , Scherer, E, Streffer, C. and Trott, K. R, eds, Springer-Verlag, Berlin, Germany, pp; Uma Devi, P., Normal tissue protection in cancer therapy: Progress and prospects (1998) Acta Oncol, 37, pp. 247-252; Riis, P., Anthonsien, P., Wulff, H.R., Folkenborg, O., Bonnevie, O., Binder, V., The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment: A double-blind trial on patients asymptomatic for one year (1973) Scand. J. Gastroenterol, 8, pp. 71-74; Svartz, N., Ett nytt sulfonamidpreparat. Forelopande meddelande (1941) Nord. Med, 9, p. 544; Hoult, J.R.S., Pharmacological and biochemical actions of sulphasalazine (1986) Drugs, 32, pp. 18-26; Azad Khan, A.K., Piris, J., Truelove, S.C., An experiment to determine the active therapeutic moiety of sulphasalazine (1977) Lancet, 2, pp. 892-895; Klotz, U., Maier, K., Fischer, C., Heinkel, K., Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease (1980) N. Engl. J. Med, 303, pp. 1499-1502; Sutherland, L.R., May, G.R., Shaffer, E.A., Sulfasalazine revisited: A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis (1993) Ann. Intern. Med, 118, pp. 540-549; Pruzanski, W., Stefanski, E., Vadas, P., Ramamurty, N.S., Inhibition of extracellular release of proinflammatory secretory phospholipase A2 by sulfasalazine (1997) Biochem. Pharmacol, 53, pp. 1901-1907; Carlin, G., Djursater, R., Smedegard, G., Inhibitory effects of sulfasalazine and related compounds on superoxide production by human polymorphonuclear leukocytes (1989) Pharmacol. Toxicol, 65, pp. 121-127; Rhodes, J.M., Bartholomew, T.C., Jewell, D.P., Inhibition of leucocyte motility by drugs used in ulcerative colitis (1981) Gut, 22, pp. 642-647; Rubinstein, A., Das, K.M., Melamed, J., Murphy, R.A., Comparative analysis of systemic immunological parameters in ulcerative colitis and idiopathic proctitis: Effect of sulfasalazine in vivo and in vitro (1978) Clin. Exp. Immunol, 33, pp. 217-224; Sheldon, P.J., Webb, C., Grindulis, K.A., Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes-clues to its clinical action? (1988) Br. J. Rheumatol, 27, pp. 344-349; Fujiwara, M., Mitsui, K., Yamamoto, I., Inhibition of proliferative responses and interleukin 2 production by salazosulfapyridine and its metabolites (1990) Jpn. J. Pharmacol, 54, pp. 121-132; Gaginella, T.S., Walsh, R.E., Sulfasalazine: Multiplicity of action (1992) Dig. Dis. Sci, 37, pp. 801-812; Gionchetti, P., Guarnieri, C., Campieri, M., Belluzzi, A., Brignola, C., Iannoe, P., Miglioli, M., Barbara, L., Scavenger effects of sulfasalazine, 5-aminosalicylic acid, olsalazine on superoxide radical generation (1991) Dig. Dis. Sci, 36, pp. 174-178; Miyachi, Y., Yoshioka, A., Imamura, S., Niwa, Y., Effect of sulfasalazine and its metabolites on the generation of reactive oxygen species (1987) Gut, 28, pp. 190-195; Pronai, L., Yukinobu, I., Lang, I., Feher, J., The oxygen centered radical scavenging activity of sulfasalazine and its metabolites. A direct protection of bowel (1992) Acta Physiol. Hung, 80, pp. 317-323; Rauch, K., Weilland, H., Behandlung der radiogenen kolitis mit salisilazosulfapyridin (azusulfidine) (1972) Strahlentherapie, 143, pp. 660-663; Kilic, D., Ozenirler, S., Egenhan, I., Dursun, A., Sulfasalazine decreases acute gastrointestinal complications due to pelvic radiotherapy (2001) Ann. Pharmacother, 35, pp. 806-810; Kilic, D., Ozenirler, S., Egenhan, I., Dursun, A., Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy (2000) Radiother. Oncol, 57, pp. 125-129; Lee, Y.S., Kang, S.K., Kim, T.H., Myong, N.H., Jang, J.J., Species, strain and sex differences in susceptibility to gamma radiation combined with diethylnitrosamine (1998) Anticancer Res, 18, pp. 1105-1109; Calabrese, E.J., Baldwin, L.A., The effects of gamma rays on longevity (2000) Biogerontology, 1, pp. 309-319; Ghosh, M.N., (1984) Fundamentals of Experimental Pharmacology, pp. 153-157. , 2nd edn. Scientific Book Agency, Calcutta, India; Geigy, J. R. (1956) Documents Geigy Scientific Tables. 5th edn. J. Board & Co. Ltd., Basle, UK, pp. 26-48; Uma Devi, P., Bisht, K.S., Vinitha, M., A comparative study of radioprotection by ocimum flavonoids and synthetic aminothiol protectors in the mouse (1998) Br. J. Radiol, 71, pp. 782-784; Savage, J.R.K., Classification and relationships of induced chromosomal structural changes (1976) J. Med. Genet, 12, pp. 103-122; Bender, M.A., Awa, A.A., Brooks, A.L., Evans, H.J., Groer, P.G., Littlefield, L.G., Pereira, C., Wachholz, B.W., Current status of cytogenetic procedures to detect and quantify previous exposures to radiation (1988) Mutat. Res, 196, pp. 103-159; Schmid, W., Chemical mutagen testing on in vivo somatic cells (1973) Agents Actions, 3, pp. 77-85; Schmid, W., The micronucleus test (1979) Mutat. Res, 31, pp. 9-15; Wijewickreme, A.N., Krejpcio, Z., Kitts, D.D., Hydroxyl scavenging activity of glucose, fructose and ribose-lysine model Maillard products (1999) J. Food Sci, 64, pp. 457-461; Cole, R.J., Tylor, N., Cole, J., Arlett, C.F., Short-term tests for transplacentally active carcinogens. I. Micronucleus formation in fetal and maternal mouse erythroblasts (1981) Mutat. Res, 80, pp. 141-157; Jagetia, G.C., Ganapathi, N.G., Treatment of mice with a herbal preparation (Liv. 52) reduces the frequency of radiation-induced chromosome damage in bone marrow (1991) Mutat. Res, 253, pp. 123-126; Jagetia, G.C., Venkatesha, V.A., Reddy, T.K., Naringin, a citrus flavonone, protects against radiation-induced chromosome damage in mouse bone marrow (2003) Mutagenesis, 18, pp. 337-343; Carrano, A.V., Heddle, J.A., The fate of chromosome aberrations (1973) J. Theor. Biol, 38, pp. 289-304; Sasaki, H., Lethal sectoring, genomic instability, and delayed division delay in HeLa S3 cells surviving alpha- or X-irradiation (2004) J. Radiat. Res, 45, pp. 497-508; Fenech, M., Cytokinesis-block micronucleus cytome assay (2007) Nat. Protoc, 2, pp. 1084-1104; Hofer, M., Mazur, L., Pospisil, M., Weiterova, L., Znojil, V., Radioprotective action of extracellular adenosine on bone marrow cells in mice exposed to gamma rays as assayed by the micronucleus test (2000) Radiat. Res, 154, pp. 217-221; Yuhas, J.M., Storer, J.B., Chemoprotection against three modes of radiation death (1969) Int. J. Radiat. Biol, 15, pp. 233-237; Uma Devi, P., Prasanna, P.G.S., Radioprotective effect of combinations of WR-2721 and mercaptopropionylglycine on mouse bone marrow chromosomes (1990) Radiat. Res, 124, pp. 165-170; Gupta, R., Uma Devi, P., Protection of mouse chromosomes against whole-body gamma irradiation by SH-compounds (1986) Br. J. Radiol, 59, pp. 625-627; Thomas, B., Uma Devi, P., Chromosome protection by WR-2721 and MPG-single and combination treatments (1987) Strahlenther Onkol, 163, pp. 807-810; Ganasoundari, A., Uma Devi, P., Rao, B.S.S., Enhancement of bone marrow radioprotection and reduction of WR-2721 toxicity by Ocimum sanctum (1998) Mutat. Res, 397, pp. 303-312; Jagetia, G.C., Aruna, R., The herbal preparation abana protects against radiation-induced micronuclei in mouse bone marrow (1997) Mutat. Res, 393, pp. 157-163; Chaubey, R.C., Bhilwade, H.N., Joshi, B.N., Chauhan, P.S., Studies on the migration of micronucleated erythrocytes from bone marrow to the peripheral blood in irradiated Swiss mice (1993) Int. J. Radiat. Biol, 63, pp. 239-245; Sudheer Kumar, M., Unnikrishnan, M.K., Uma Devi, P., Effect of 5-aminosalicylic acid on radiation-induced micronuclei in mouse bone marrow (2003) Mutat. Res, 527, pp. 7-14; Grzelinska, E., Bartkowiak, A., Bartosz, G., Leyko, W., Effect of •OH scavengers on radiation damage to the erythrocyte membrane (1982) Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med, 41, pp. 473-481; Joshi, R., Kumar, S., Unnikrishnan, M., Mukherjee, T., Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and sulfapyridine: Mechanistic aspects and antioxidant activity (2005) Free Radic. Res, 39, pp. 1163-1172; Bishop, J.B., Witt, K.L., Gulati, D.K., MacGregor, J.T., Evaluation of the mutagenicity of the anti-inflammatory drug salicylazosulfapyridine (SASP) (1990) Mutagenesis, 5, pp. 549-554; Iatropoulos, M.J., Williams, G.M., Abdo, K.M., Kari, F.W., Hart, R.W., Mechanistic studies on genotoxicity and carcinogenicity of salicylazosulfapyridine an anti-inflammatory medicine (1997) Exp. Toxicol. Pathol, 49, pp. 15-28; Uma Devi, P., Nagarathnam, A., Rao, B.S.S., DNA damage and repair (2000) Introduction to Radiation Biology, pp. 52-64. , Churchill Livingstone Pvt. Ltd, New Delhi, India, pp; Sasaki, M.S., Matsubara, S., Free radical scavenging in protection of human lymphocytes against chromosome aberration formation by gamma-ray irradiation (1977) Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med, 32, pp. 439-445; Roots, R., Okada, S., Protection of DNA molecules of cultured mammalian cells from radiation-induced single-strand scissions by various alcohols and SH compounds (1972) Int J. Radiat. Biol. Relat. Stud. Phys. Chem. Med, 21, pp. 329-342; Okada, S., Nakamura, N., Sasaki, K., Radioprotection of intracellular genetic material (1983) Radioprotection and Anticarcinogens, pp. 339-356. , Nygaard, O. F. and Simic, M. G, eds, Academic Press, New York, pp; Shimoi, K., Masuda, S., Shen, B., Furugori, M., Kinae, N., Radiation protection effect of antioxidative plant flavonoids in mice (1996) Mutat. Res, 350, pp. 153-161; Abraham, S.K., Sarma, L., Kesavan, P.C., Protective effects of chlorogenic acid, curcumin and β-carotene against c-radiation-induced in vivo chromosomal damage (1993) Mutat. Res, 303, pp. 109-112; Sarma, L., Kesavan, P.C., Protective effects of vitamin C and E against γ-ray-induced chromosomal damage in mouse (1993) Int. J. Radiat. Biol, 63, pp. 759-764; Umegaki, K., Ikegami, S., Inoue, K., Ichikawa, T., Kobayashi, S., Soeno, N., Tomebachi, K., Beta-carotene prevents X-ray induction of micronuclei in human lymphocytes (1994) Am. J. Clin. Nutr, 59, pp. 409-412; O'Neill, P., Fielden, E.M., Primary free radical processes in DNA (1993) Advances in Radiation Biology, pp. 53-120. , Lett, J. T. and Sinclair, W. K, eds, Academic Press, New York, pp; Uma Devi, P., Ganasoundari, A., Rao, B.S.S., Srinivasan, K.K., In vivo radioprotection by ocimum flavonoids: Survival of mice (1999) Radiat. Res, 151, pp. 74-78; Maisin, J.R., Albert, C., Henry, A., Reduction of short-term radiation lethality by biological response modifiers given alone or in association with other chemical protectors (1993) Radiat. Res, 135, pp. 332-337; Michalowski, A.D., On radiation damage to normal tissue and treatment (1994) Acta Oncol, 33, pp. 139-157; Satyamitra, M., Uma Devi, P., Murase, H., Kagiya, V.T., In vivo postirradiation protection by a vitamin E analog, alpha-TMG (2003) Radiat. Res, 160, pp. 655-661; Farooqi, Z., Kesavan, P.C., Radioprotection by caffeine pre- and post-treatment in the bone marrow chromosomes of mice given whole-body c-irradiation (1992) Mutat. Res, 269, pp. 225-230; Gout, P.W., Buckley, A.R., Simms, C.R., Bruchovsky, N., Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: A new action for an old drug (2001) Leukemia, 15, pp. 1633-1640; Chung, W.J., Lyons, S.A., Nelson, G.M., Hamza, H., Gladson, C.L., Gillespie, G.Y., Sontheimer, H., Inhibition of cystine uptake disrupts the growth of primary brain tumors (2005) J. Neurosci, 25, pp. 7101-7110; Doxsee, D.W., Gout, P.W., Kurita, T., Sulfasalazine-induced cystine starvation: Potential use for prostate cancer therapy (2007) Prostate, 67, pp. 162-171; Fischer-Nielsen, A., Poulsen, H.E., Loft, S., 8-Hydroxydeoxyguanosine in vitro: Effects of glutathione, ascorbate and 5-aminosalicylic acid (1992) Free Radic. Biol. Med, 13, pp. 121-126
PY - 2008
Y1 - 2008
N2 - Sulfasalazine (SAZ), a prescribed drug for inflammatory bowel disease, is a potent scavenger of reactive oxygen species. The present study was undertaken to ascertain its ability to protect against gamma radiation-induced damage. Acute toxicity of the drug was studied taking 24-h, 72-h and 30-day mortality after a single intraperitoneal injection of 400-1200 mg/kg body weight (b.wt.) of the drug. The drug LD50 for 24- and 72-h/30-day survival were found to be 933 and 676 mg/kg b.wt., respectively. The optimum time of drug administration and drug dose-dependent effect on in vivo radiation protection of bone marrow chromosomes was studied in mice. Injection of 30-180 mg/kg SAZ 30 min before gamma irradiation (RT) with 4 Gy produced a significant dose-dependent reduction in the RT-induced percent aberrant metaphases and in the frequency of micronucleated erythrocytes at 24 h after exposure, with a corresponding decrease in the different types of aberrations. The optimum dose for protection without drug toxicity was 120 mg/kg b.wt. At this dose, SAZ produced >60% reduction in the RT-induced percent aberrant metaphases and micronucleated erythrocytes. SAZ also produced a significant increase in the ratio of polychromatic erythrocytes to normochromatic erythrocytes from that of irradiated control. Injection of 120 mg/kg of the drug 60 or 30 min before or within 15 min after 4 Gy whole-body RT resulted in a significant decrease in the percent of aberrant metaphases and in the frequency of micronucleated erythrocytes at 24 h post-irradiation; the maximum effect was seen when the drug was administered 30 min before irradiation. These results show that SAZ protect mice against RT-induced chromosomal damage and cell cycle progression delay. SAZ also protected plasmid DNA (pGEM-7Zf) against Fenton's reactant-induced breaks, suggesting free radical scavenging as one of the possible mechanism for radiation protection. © The Author 2008. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved.
AB - Sulfasalazine (SAZ), a prescribed drug for inflammatory bowel disease, is a potent scavenger of reactive oxygen species. The present study was undertaken to ascertain its ability to protect against gamma radiation-induced damage. Acute toxicity of the drug was studied taking 24-h, 72-h and 30-day mortality after a single intraperitoneal injection of 400-1200 mg/kg body weight (b.wt.) of the drug. The drug LD50 for 24- and 72-h/30-day survival were found to be 933 and 676 mg/kg b.wt., respectively. The optimum time of drug administration and drug dose-dependent effect on in vivo radiation protection of bone marrow chromosomes was studied in mice. Injection of 30-180 mg/kg SAZ 30 min before gamma irradiation (RT) with 4 Gy produced a significant dose-dependent reduction in the RT-induced percent aberrant metaphases and in the frequency of micronucleated erythrocytes at 24 h after exposure, with a corresponding decrease in the different types of aberrations. The optimum dose for protection without drug toxicity was 120 mg/kg b.wt. At this dose, SAZ produced >60% reduction in the RT-induced percent aberrant metaphases and micronucleated erythrocytes. SAZ also produced a significant increase in the ratio of polychromatic erythrocytes to normochromatic erythrocytes from that of irradiated control. Injection of 120 mg/kg of the drug 60 or 30 min before or within 15 min after 4 Gy whole-body RT resulted in a significant decrease in the percent of aberrant metaphases and in the frequency of micronucleated erythrocytes at 24 h post-irradiation; the maximum effect was seen when the drug was administered 30 min before irradiation. These results show that SAZ protect mice against RT-induced chromosomal damage and cell cycle progression delay. SAZ also protected plasmid DNA (pGEM-7Zf) against Fenton's reactant-induced breaks, suggesting free radical scavenging as one of the possible mechanism for radiation protection. © The Author 2008. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved.
U2 - 10.1093/mutage/gen005
DO - 10.1093/mutage/gen005
M3 - Article
SN - 0267-8357
VL - 23
SP - 285
EP - 292
JO - Mutagenesis
JF - Mutagenesis
IS - 4
ER -